Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

Friedreich's ataxia is a widespread hereditary ataxia type, affecting a minimum of one in every 50,000 individuals. It is c ...

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Biogen (BIIB – Research Report), with a price ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Shares of Biogen Inc. BIIB advanced 2.06% to $118.89 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 2.51% to 5,287.76 and ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target ...

Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.

Motor improvements in SMA adults treated with Spinraza paralleled a boost in electrical impulses along nerves that supply ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

Powerhouse corporations have secured a total of more than 170 megawatts of affordable solar energy from two upcoming solar ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | The Trump administration is expected to announce tariffs on pharmaceuticals ...